Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Autolus Therapeutics plc AUTL

Healthcare Biotechnology
Autolus Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. It is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:AUTL)

Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO

GlobeNewswire 23 hours ago

Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

GlobeNewswire 2 days ago

Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)

GlobeNewswire April 2, 2024

Autolus Therapeutics Announces Changes to its Board of Directors

GlobeNewswire April 1, 2024

Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates

GlobeNewswire March 14, 2024

Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site

GlobeNewswire March 12, 2024

Autolus Therapeutics announces publication in Blood Cancer Journal

GlobeNewswire March 11, 2024

Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024

GlobeNewswire February 29, 2024

Autolus Therapeutics announces publication in Nature Communications 

GlobeNewswire February 22, 2024
View More News ››

Opinion & Analysis (NDAQ:AUTL)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:AUTL)

$iMIN making moves in Ethereum Crypto !! 🚀🚀🚀🚀🚀

iMining Launches Fractional Staking to Enable Retail Investors to Participate in Ethereum 2.0's Proof-Of-Stake Mining Vancouver...
Saaaa1 - May 6, 2021

it's a buy today for me

at bout 15 U.S.per share it is worth my money,it should be a triple for me as my target price is about $45 U.S. per share,so glta,but my...
coolfooldumbguy - September 6, 2019
View more Bullboard ››

Africa Oil Corp.

Africa Oil Corp.

Africa Oil Corp. is a Canadian oil and gas company with producing and development assets in deepwater Nigeria and an ...
View More »